B. Metzler seel. Sohn & Co. Holding AG Makes New $4.67 Million Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 9,235 shares of the company’s stock, valued at approximately $4,666,000.

Several other institutional investors have also recently made changes to their positions in IDXX. Crewe Advisors LLC bought a new position in IDEXX Laboratories in the 1st quarter worth about $26,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories in the second quarter worth approximately $27,000. Institutional & Family Asset Management LLC purchased a new stake in IDEXX Laboratories in the second quarter valued at approximately $28,000. E Fund Management Hong Kong Co. Ltd. lifted its position in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC grew its stake in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.8 %

Shares of IDXX opened at $416.34 on Wednesday. The firm has a fifty day simple moving average of $465.52 and a two-hundred day simple moving average of $481.99. IDEXX Laboratories, Inc. has a twelve month low of $404.74 and a twelve month high of $583.39. The stock has a market capitalization of $34.09 billion, a P/E ratio of 40.15, a PEG ratio of 3.67 and a beta of 1.36. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same period last year, the firm earned $2.53 earnings per share. IDEXX Laboratories’s quarterly revenue was up 6.6% on a year-over-year basis. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on IDXX. BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective for the company. Barclays dropped their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. JPMorgan Chase & Co. decreased their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Piper Sandler restated a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.